Inari Medical, Inc. (NASDAQ: NARI) reported Q4 EPS of $0.13, $0.12 better than the analyst estimate of $0.01. Revenue for the quarter came in at $48.6 million versus the consensus estimate of $41.08 million.

Fourth Quarter Revenue and Business Highlights:

• Treated a record 4,600 patients, up 24% sequentially, driving revenue of $48.6 million, which was up 26% sequentially and 144% over the prior year period.
• Introduction of multiple new products including the Triever 20 Curve, which along with FDA clearance for clot in transit, opens a new $200 million market opportunity.
• Presentation of data from the CLOUT DVT registry showing excellent safety and effectiveness in the most challenging subset of patients with chronic clot.
• Ended the quarter with $164.2 million in cash, cash equivalents, and short-term investments.

“During Q4 we made important progress in our mission to treat and transform the lives of our patients,” said Bill Hoffman, CEO of Inari Medical. “We treated a record number of patients, expanded our commercial footprint, presented positive data on chronic clot patients, introduced two new products which expand our addressable market and completed our first patient treatments in Europe. Our team continues to execute crisply on all five of our growth drivers. We remain committed to our cause, and we are thankful for the opportunity to serve our patients, teammates, and customers.”

GUIDANCE:

Inari Medical, Inc. sees Q1 2021 revenue of $54-56 million, versus the consensus of $41.68 million.

Inari Medical, Inc. sees FY2021 revenue of $225-235 million, versus the consensus of $181.5 million.

Despite ongoing challenges and uncertainties in its operating environment due to the COVID-19 pandemic, Inari Medical is providing financial guidance as follows:

• For the first quarter of 2021, revenue of $54 to $56 million, and,
• For the full-year 2021, revenue of $225 to $235 million.

For earnings history and earnings-related data on Inari Medical, Inc. (NARI) click here.